Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
ASIAN entrepreneur Ranjit Singh Boparan's firm reported a £23.1 million loss last year, only a slight improvement on the £28.5m pre-tax loss the company recorded in 2022.
The UK's largest poultry producer experienced a second consecutive year of losses due to the rapid increase in interest rates and unexpected inflation in its pension scheme, The Times reported.
Boparan owns 2 Sisters Food Group, Bernard Matthews and several high street restaurant chains.
The net financing charges at 2 Sisters surged by over 25 per cent to £62.3m, indicating a rise in the company's debt to a net £526m in 2023, up from £488m in the previous year. This escalation in debt resulted in a ratio of 5.1 times adjusted earnings before interest, taxes, and other items, compared to a multiple of 4.9 in 2022.
Rising financing costs offset the revenue increase from £2.8 billion to £3bn. Prices were raised to tackle double-digit operating cost inflation, including labour, energy, and feed prices. However, the operating margin slipped to 1.3 per cent from 1.4 per cent in 2022.
In March, it was reported that Nigel Williams, a former Starbucks executive, will oversee a refinancing of the firm's debts ahead of a deadline of June next year.
In the past few years, Boparan has sold off brands like part of its Fox's Biscuits business and Matthew Walker Christmas Puddings. The money earned from these sales was used to reduce the company's debt burden.
“In reality it was a resilient performance set against war in Europe, hyper-inflation and post-Covid labour challenges, and associated inflationary costs are reflected in the numbers," Boparan was quoted as saying.
The company expressed cautious optimism about its financial performance for the current fiscal year. Additionally, worker shortages at its poultry processing plants had shown signs of improvement.
Boparan Holdings serves as the parent company of 2 Sisters Food Group, which supplies the majority of the UK's supermarkets and major retailers in the Netherlands with chicken and turkey products. Moreover, it produces own-label packaged foods like pizzas, soups, and ready meals. The Boparan family also holds ownership of Bernard Matthews, the UK's leading turkey supplier.
Established in 1993, 2 Sisters operates across 23 food manufacturing sites in the UK, the Netherlands, and Poland, employing approximately 15,000 people.
Last July, the deficit in the company's defined benefit pension scheme soared to £89.3m, attributing this increase to higher-than-expected inflation and lower investment returns. This shortfall primarily stems from Northern Foods, which Boparan acquired over a decade ago in a £342m deal. Boparan has committed to injecting £235m in cash until 2031 to address the deficit.
The company clarified that the reported pension deficit was significantly influenced by market fluctuations at the time of reporting, adding that a 52-week snapshot does not accurately reflect the situation. Moreover, it noted that the deficit has decreased by more than half over the past five years.
Aside from their food-related ventures, Boparan, 57, and his wife, Baljinder Kaur Boparan, own nine high street restaurant chains, including Gourmet Burger Kitchen, Giraffe, and Carluccio's.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.